Chapter 29: Sulfonamides & Nitroimidazole Antibiotics

Sulfonamides & Nitroimidazole Antibiotics begins by defining sulfonamides as the first synthetic bacteriostatic agents which function by competitively inhibiting the bacterial synthesis of folic acid, a vital nutrient for bacterial growth, thereby halting replication without affecting human cells that acquire folate through diet. A major focus is placed on the synergistic combination of trimethoprim and sulfamethoxazole (TMP-SMZ), which blocks sequential steps in protein and nucleic acid synthesis to achieve a powerful bactericidal effect, making it a primary choice for urinary tract infections, otitis media, and preventing Pneumocystis carinii pneumonia in immunocompromised patients. The text outlines essential pharmacokinetics, emphasizing that while older formulations caused crystalluria due to poor solubility, modern protocols still require significant fluid intake to flush the kidneys and prevent stone formation. Significant attention is given to adverse reactions, including severe hypersensitivity responses like Stevens-Johnson syndrome, blood dyscrasias such as aplastic anemia and agranulocytosis, and photosensitivity, necessitating patient education on sun protection. The chapter also covers topical sulfonamides like silver sulfadiazine and mafenide acetate, which are crucial for preventing sepsis in second- and third-degree burns, as well as ophthalmic sulfacetamide for eye infections. Furthermore, the discussion details nitroimidazoles, specifically metronidazole and tinidazole, which disrupt DNA structures to treat anaerobic bacterial infections like Clostridium difficile-associated diarrhea (CDAD) and protozoal conditions such as trichomoniasis and amebiasis. Nursing considerations for these drugs include monitoring for the disulfiram-like reaction when combined with alcohol and assessing for neurotoxicity. Finally, the summary reviews miscellaneous antibacterials like chloramphenicol for life-threatening infections, quinupristin-dalfopristin for vancomycin-resistant strains, and monoclonal antibodies for anthrax, underscoring the nursing process in assessment, drug administration, and evaluating therapeutic outcomes.